Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension.

MLA

Daly, Caroline M., et al. “Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension.” Journal of the American Heart Association, vol. 10, no. 20, Oct. 2021, p. e021409. EBSCOhost, https://doi.org/10.1161/JAHA.120.021409.

APA

Daly, C. M., Griffiths, M., Simpson, C. E., Yang, J., Damico, R. L., Vaidya, R. D., Williams, M., Brandal, S., Jone, P.-N., Polsen, C., Ivy, D. D., Austin, E. D., Nichols, W. C., Pauciulo, M. W., Lutz, K., Nies, M. K., Rosenzweig, E. B., Hirsch, R., Yung, D., & Everett, A. D. (2021). Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension. Journal of the American Heart Association, 10(20), e021409. https://doi.org/10.1161/JAHA.120.021409

Chicago

Daly, Caroline M, Megan Griffiths, Catherine E Simpson, Jun Yang, Rachel L Damico, R Dhananjay Vaidya, Monica Williams, et al. 2021. “Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension.” Journal of the American Heart Association 10 (20): e021409. doi:10.1161/JAHA.120.021409.